文献速递外周动脉疾病

血小板与淋巴细胞比值作为严重肢体威胁性缺血患者肌少症标志物的价值

Usefulness of Platelet-to-Lymphocyte Ratio as a Marker of Sarcopenia for Critical Limb Threatening Ischemia.
PubMed 文献 · Ann Vasc Surg · 2020-05-29

肌少症定义为腰大肌指数(PMI)男性<5.5 cm2/m2、女性<4.0 cm2/m2。结果显示肌少症组PLR显著高于非肌少症组(均值332.1 vs 204.6,P=0.02),PLR≥292.5诊断肌少症的敏感性31.3%、特异性91.7%。结论认为PLR可能有助于识别预后不良的CLTI患者亚组,但因其敏感性低,不适合作为肌少症的标志物。

要点

  • 肌少症组PLR显著高于非肌少症组(均值332.1 vs 204.6,P=0.02)。
  • PLR≥292.5诊断肌少症的敏感性31.3%、特异性91.7%。
  • 肌少症组30天并发症发生率56.3%,非肌少症组10.4%(P<0.001)。

核心结论

  • PLR可能有助于识别预后不良的CLTI患者亚组,但因其敏感性低,不适合作为肌少症的标志物。

研究设计与样本

  • 肌少症定义为腰大肌指数(PMI)男性<5.5 cm2/m2、女性<4.0 cm2/m2。
  • PLR基于术前系统性血液分析计算,通过受试者工作特征(ROC)曲线分析诊断效能。

主要发现

  • 肌少症组16例(平均PMI 4.30 cm2/m2;IQR 3.45-5.17),非肌少症组48例(平均PMI 7.34 cm2/m2;IQR 6.58-8.01)。
  • 两组在人口学特征、临床特征、心血管危险因素、合并症或血运重建方式上无差异。
  • 肌少症组PLR显著高于非肌少症组(均值332.1;IQR 158.2-320.7 vs 均值204.6;IQR 133.8-265.6)(P=0.02)。
  • PLR≥292.5诊断肌少症的敏感性31.3%、特异性91.7%。
  • 肌少症组30天死亡率12.5%,非肌少症组2.1%(P=0.15);30天并发症发生率肌少症组56.3%,非肌少症组10.4%(P<0.001)。

关键数值与推荐

  • 肌少症定义:PMI男性<5.5 cm2/m2,女性<4.0 cm2/m2。
  • PLR≥292.5作为肌少症诊断标志物的敏感性31.3%、特异性91.7%。

临床怎么用

  • PLR计算简便快速,或可辅助识别CLTI中预后不良的肌少症高危患者。
  • 因敏感性低,PLR不能替代影像学测量作为肌少症的确诊标志物。

局限性

  • 肌少症组仅16例,诊断效能评估可能受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcopenia is a factor of poor prognosis for patients with critical limb threatening ischemia (CLTI), but its diagnosis requires imaging measurements and is time consuming. We investigated whether preoperative platelet-to-lymphocyte ratio (PLR) could be an easy and rapid marker of sarcopenia. METHODS: Patients treated for CLTI between January 2019 and July 2019 were included in this single-center retrospective study. Sarcopenia was defined by a psoas muscle index (PMI) <5.5 cm2/m2 in men, and <4.0 cm2/m2 in women. PLR was calculated for all patients based on their systematic preoperative blood analysis. The diagnostic power of PLR was analyzed through a receiver operating characteristic (ROC) curve. Early outcomes of sarcopenic patients in terms of 30-day mortality and 30-day morbidity were retrieved. RESULTS: Sixty-four patients were included in the study: 48 nonsarcopenic patients (mean PMI 7.34 cm2/m2; interquartile range [IQR] 6.58-8.01) and 16 sarcopenic patients (mean PMI 4.30 cm2/m2; IQR 3.45-5.17). No difference was found between both groups regarding patient demographics, clinical characteristics, cardiovascular risk factors, comorbidities, or revascularization modalities. PLR was significantly higher in the sarcopenic group (mean 332.1; IQR 158.2-320.7) compared with the nonsarcopenic group (mean 204.6; IQR 133.8-265.6) (P = 0.02). A PLR value ≥292.5 was shown to be a diagnostic marker for sarcopenia based on the ROC curve (sensitivity 31.3%, specificity 91.7%). Thirty-day mortality was 12.5% in the sarcopenic group and 2.1% in the nonsarcopenic group (P = 0.15); 30-day morbidity was 56.3% in the sarcopenic group and 10.4% in the nonsarcopenic group (P < 0.001). CONCLUSIONS: PLR might help identifying a subgroup of CTLI patients associated with poor prognosis but does not seem appropriate to be used as a marker of sarcopenia given its low sensitivity.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Pizzimenti M, Charles AL, Riou M, et al. Usefulness of Platelet-to-Lymphocyte Ratio as a Marker of Sarcopenia for Critical Limb Threatening Ischemia. Ann Vasc Surg. 2020. PMID: 32479878. doi:10.1016/j.avsg.2020.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。